Artios Pharma

View the org chart displaying its 23 main executives

Most searched biographies at Artios Pharma

• Niall Martin, Chief Executive Officer and Director
• Raphael Wisniewski, Director
• Samantha Truex, Director

Popular executive movements at Artios Pharma

• Chris Liu has joined the company as Director  (posted on April 12 2024).
• Christine Silverstein has joined the company as Chief Financial Officer  (posted on February 8 2024).

Create your alert
to follow the executive moves at Artios Pharma.

Artios Pharma has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Artios Pharma

• Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD - Artios Pharma
• Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer - Artios Pharma
• Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023 - Artios Pharma
• Press release Archives - Page 4 of 4 - Artios Pharma
• Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023 - Artios Pharma
• IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer - Artios Pharma
• Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer - Artios Pharma
• Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer - Artios Pharma
• Artios Appoints Samantha Truex to Board of Directors - Artios Pharma
• More exciting press coverage following $153 Million financing – Series C | Artios
• View more press releases Close

Social media about Artios Pharma

• Artios Pharma on Wikipedia, Google News & Yahoo Finance
• Artios Pharma on LinkedIn, Twitter & YouTube

Contact by email its executives including Niall Martin

Call Artios Pharma at +44 122...

View the org chart

Register to receive your alert

Report an error